MarketPulse

MASH

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Gyre Therapeutics Posts 10% Revenue Growth but Guides Lower Amid Strategic Pivot

Gyre Therapeutics posts 10% FY2025 revenue growth to $116.6M, guides 2026 lower due to regulatory prioritization and Cullgen acquisition for TPD expansion.
GYRErevenue guidanceclinical trial